Bicara Therapeutics reported total assets of $512.24M and total liabilities of $43.48M for the quarter ended Jun 2026, up 12.9% year over year. This balance sheet covers 12 quarters of results from Sep 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Current Assets | ||||||||||||
| Cash & EquivalentsCash & Equiv. | 230.44M | 520.80M | 489.71M | 462.10M | 436.61M | 171.67M | 96.69M | 323.46M | 96.60M | |||
| Prepaid Assets | 0.63M | 0.76M | 12.82M | 8.69M | 7.79M | 7.21M | 7.25M | 5.16M | 6.56M | |||
| Current Assets | 231.07M | 521.51M | 502.53M | 470.75M | 444.39M | 297.37M | 422.05M | 544.91M | 503.82M | |||
| Non-Current Assets | ||||||||||||
| Property, Plant & Equipment (Net) | 0.20M | 0.13M | 0.15M | 0.14M | 0.12M | 0.14M | 0.33M | 0.35M | 0.36M | |||
| Long-Term Investments | 117.42M | |||||||||||
| Other Non-Current Assets | 2.09M | 2.12M | 6.62M | 6.63M | 6.84M | 7.79M | 6.91M | 6.91M | 6.91M | |||
| Non-Current Assets | 2.91M | 2.66M | 7.46M | 7.32M | 9.20M | 127.32M | 8.94M | 8.68M | 8.42M | |||
| Assets | 233.98M | 524.17M | 510.00M | 478.08M | 453.59M | 424.69M | 430.99M | 553.60M | 512.24M | |||
| Liabilities | ||||||||||||
| Current Liabilities | ||||||||||||
| Accounts Payables | 2.14M | 1.53M | 3.89M | 2.35M | 2.04M | 3.00M | 5.51M | 6.19M | 7.43M | |||
| Payables | 2.14M | 1.53M | 3.89M | 2.35M | 2.04M | 3.00M | 5.51M | 6.19M | 7.43M | |||
| Accumulated Expenses | 8.05M | 10.41M | 12.88M | 12.28M | 12.00M | 14.99M | 18.90M | 29.95M | 33.67M | |||
| Current Leases | 0.28M | 0.31M | 0.61M | 0.59M | 1.07M | 1.09M | 1.12M | 1.14M | 1.16M | |||
| Total Current Liabilities | 15.09M | 14.48M | 17.99M | 19.12M | 17.23M | 21.03M | 28.95M | 39.34M | 43.48M | |||
| Non-Current Liabilities | ||||||||||||
| Preferred Stock Liabilities | 85.00M | 367.28M | 164.60M | 164.60M | ||||||||
| Operating Leases | 0.37M | 0.14M | 0.13M | 1.16M | 0.88M | 0.59M | 0.30M | |||||
| Other Non-Current Liabilities | 0.02M | |||||||||||
| Total Non-Current Liabilities | 15.46M | 14.62M | 18.12M | |||||||||
| Total Liabilities | 137.11M | 15.47M | 160.08M | 174.78M | 14.62M | 18.12M | 19.12M | 18.39M | 21.91M | 29.54M | 39.64M | 43.48M |
| Shareholder's Equity | ||||||||||||
| Common Equity | -137.11M | -148.77M | -160.08M | -174.78M | 509.56M | 491.88M | 458.96M | 435.20M | 402.78M | 401.45M | 513.96M | 468.77M |
| Liabilities and Shareholders Equity | 233.98M | 524.17M | 510.00M | 478.08M | 453.59M | 424.69M | 430.99M | 553.60M | 512.24M | |||
| Retained Earnings | -153.02M | 709.61M | 712.88M | 716.81M | 720.44M | 724.49M | 760.17M | 929.37M | 939.94M | |||
| Treasury Shares | 81.79M | 119.60M | 119.60M | 119.60M | 7.00M |